Results 91 to 100 of about 7,464 (222)

Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy

HIV/AIDS: Research and Palliative Care, 2015
Nils von Hentig HIV Center, Medical Department II, Hospital of the JW Goethe-University, Frankfurt, BAG Darab-Kaboly/von Hentig, General Medicine and HIV Care, Frankfurt am Main, Germany Abstract: The pharmacoenhancement of plasma concentrations of ...
von Hentig N
doaj  

Increased insulin resistance following switch from efavirenz to cobicistat-boosted elvitegravir

Antiviral Therapy
Background Integrase strand transfer inhibitors (INSTIs) have been associated with excess weight gain in people living with HIV compared to other antiretroviral agents. The mechanisms that underlie these effects are not well defined.
Richard Taylor Pickering, Archana Asundi, Alex Olson, Katie Soden, Daniel R Kuritzkes, Nina H Lin   +5 more
doaj   +1 more source

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

AIDS Research and Therapy, 2019
Background Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals)
Lucia Taramasso, Elena Ricci, Antonio Cascio, Laura Valsecchi, Barbara Menzaghi, Nicola Squillace, Paolo Maggi, Giuseppe Vittorio De Socio, Chiara Dentone, Giordano Madeddu, Giovanni F. Pellicanò, Leonardo Calza, Goffredo Angioni, Paolo Bonfanti, Antonio Di Biagio, CISAI Study Group   +15 more
doaj   +1 more source

Prospective study to assess progression of renal markers after interruption of tenofovir due to nephrotoxicity [PDF]

, 2016
Background. Prospective studies about the reversibility of tenofovir disoproxil fumarate- (TDF-) related renal impairment remain scarce. Methods. This is an observational prospective study including all patients that presented at our HIV Unit who ...
Bonjoch Badia, Anna, Clotet Sala, Bonaventura, Echeverria Liras, Patricia, Estany Quera, Carla, Negredo Puigmal, Eugènia, Puig, Jordi, Pérez Álvarez, Nuria   +6 more
core   +5 more sources

Delayed Clearance of Viral RNA in Sputum for Severity COVID-19 Patients with Initial High Viral Load

Infection and Drug Resistance, 2022
Hong Zhao,* Huilan Tu,* Xia Yu,* Junwei Su, Xuan Zhang, Kaijin Xu, Yu Shi, Yunqing Qiu, Jifang Sheng State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National ...
Zhao H, Tu H, Yu X, Su J, Zhang X, Xu K, Shi Y, Qiu Y, Sheng J   +8 more
doaj  

Cardiovascular risk and dyslipidemia among persons living with HIV: A review [PDF]

, 2017
Background: Aim of this review is to focus the attention on people living with HIV infection at risk of developing a cardiovascular event. What is or what would be the most suitable antiretroviral therapy Which statin or fibrate to reduce the risk How to
Cicalini, S, D'Abbraccio, M, d'Ettorre, G, Di Biagio, A, Maggi, P, Martinelli, C, Nunnari, G, Rusconi, S, Sighinolfi, L, Spagnuolo, V, Squillace, N   +10 more
core   +3 more sources

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

HIV Research & Clinical Practice, 2019
Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian ...
Yeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, Amanda Clarke, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Winai Ratanasuwan, Sasisopin Kiertiburanakul, Kiat Ruxrungtham, SangYoun Yang, Susan Guo, YaPei Liu, Moupali Das, Do Tran, Damian McColl, Roberto Corales, Chris Nguyen, David Piontkowsky   +17 more
doaj   +1 more source

Pharmacokinetic interaction of riociguat and antiretroviral combination regimens in HIV-1-infected adults

Pulmonary Circulation, 2019
Riociguat, a first-in-class soluble guanylate cyclase stimulator, is approved for the treatment of pulmonary arterial hypertension (PAH), a serious potential complication of human immunodeficiency virus (HIV) infection. This open-label study investigated
Edwin DeJesus, Soundos Saleh, Sue Cheng, Dorina van der Mey, Corina Becker, Reiner Frey, Sigrun Unger, Wolfgang Mueck   +7 more
doaj   +1 more source

Highlights from the 9th IAS conference on HIV science, 23-26 July 2017, Paris, France [PDF]

, 2017
The 9th International AIDS Society Conference on HIV Science (IAS 2017) took place at the Palais des Congrès, in Paris, France, from 23 to 26 July 2017, chaired by Linda-Gail Bekker and Jean-François Delfraissy. It was organised by the International AIDS
Barber, Tristan J, Kinloch-de Loës, Sabine, Psomas, Christina K, Rutsaert, Sofie   +3 more
core   +2 more sources

A 45-year-old Female with an Atypical Presentation of Pharyngitis [PDF]

, 2020
Introduction: Emergency physicians are trained to treat a variety of ailments in the emergency department (ED), some of which are emergent, while others are not. A common complaint seen in the ED is a sore throat.
Carney, Michael B., Glickman, Andrew A., Rodgers, Brian, Schander, Artur, Weber, Nancy   +4 more
core